3.20.1 html 479 559 1 true 141 0 false 5 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.novabaypharma.com/20191231/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://www.novabaypharma.com/20191231/role/statement-consolidated-balance-sheets- Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://www.novabaypharma.com/20191231/role/statement-consolidated-balance-sheets-parentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.novabaypharma.com/20191231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss- Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.novabaypharma.com/20191231/role/statement-consolidated-statements-of-stockholders-equity Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Cash Flows Sheet http://www.novabaypharma.com/20191231/role/statement-consolidated-statements-of-cash-flows- Consolidated Statements of Cash Flows Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Organization Sheet http://www.novabaypharma.com/20191231/role/statement-note-1-organization Note 1 - Organization Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Summary of Significant Accounting Policies Sheet http://www.novabaypharma.com/20191231/role/statement-note-2-summary-of-significant-accounting-policies Note 2 - Summary of Significant Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Fair Value Measurements Sheet http://www.novabaypharma.com/20191231/role/statement-note-3-fair-value-measurements Note 3 - Fair Value Measurements Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets Sheet http://www.novabaypharma.com/20191231/role/statement-note-4-prepaid-expenses-and-other-current-assets Note 4 - Prepaid Expenses and Other Current Assets Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Inventory Sheet http://www.novabaypharma.com/20191231/role/statement-note-5-inventory Note 5 - Inventory Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Property and Equipment Sheet http://www.novabaypharma.com/20191231/role/statement-note-6-property-and-equipment Note 6 - Property and Equipment Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Accrued Liabilities Sheet http://www.novabaypharma.com/20191231/role/statement-note-7-accrued-liabilities Note 7 - Accrued Liabilities Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Commitments and Contingencies Sheet http://www.novabaypharma.com/20191231/role/statement-note-8-commitments-and-contingencies Note 8 - Commitments and Contingencies Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Related Party Notes Payable Notes http://www.novabaypharma.com/20191231/role/statement-note-9-related-party-notes-payable- Note 9 - Related Party Notes Payable Notes 15 false false R16.htm 015 - Disclosure - Note 10 - Convertible Note Sheet http://www.novabaypharma.com/20191231/role/statement-note-10-convertible-note- Note 10 - Convertible Note Notes 16 false false R17.htm 016 - Disclosure - Note 11 - Warrant Liability Sheet http://www.novabaypharma.com/20191231/role/statement-note-11-warrant-liability Note 11 - Warrant Liability Notes 17 false false R18.htm 017 - Disclosure - Note 12 - Stockholders' Equity Sheet http://www.novabaypharma.com/20191231/role/statement-note-12-stockholders-equity Note 12 - Stockholders' Equity Notes 18 false false R19.htm 018 - Disclosure - Note 13 - Equity-based Compensation Sheet http://www.novabaypharma.com/20191231/role/statement-note-13-equitybased-compensation Note 13 - Equity-based Compensation Notes 19 false false R20.htm 019 - Disclosure - Note 14 - License, Collaboration and Distribution Agreements Sheet http://www.novabaypharma.com/20191231/role/statement-note-14-license-collaboration-and-distribution-agreements- Note 14 - License, Collaboration and Distribution Agreements Notes 20 false false R21.htm 020 - Disclosure - Note 15 - Employee Benefit Plan Sheet http://www.novabaypharma.com/20191231/role/statement-note-15-employee-benefit-plan Note 15 - Employee Benefit Plan Notes 21 false false R22.htm 021 - Disclosure - Note 16 - Income Taxes Sheet http://www.novabaypharma.com/20191231/role/statement-note-16-income-taxes Note 16 - Income Taxes Notes 22 false false R23.htm 022 - Disclosure - Note 17 - Related Party Transactions Sheet http://www.novabaypharma.com/20191231/role/statement-note-17-related-party-transactions Note 17 - Related Party Transactions Notes 23 false false R24.htm 023 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.novabaypharma.com/20191231/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.novabaypharma.com/20191231/role/statement-note-2-summary-of-significant-accounting-policies 24 false false R25.htm 024 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) Sheet http://www.novabaypharma.com/20191231/role/statement-note-2-summary-of-significant-accounting-policies-tables Note 2 - Summary of Significant Accounting Policies (Tables) Tables http://www.novabaypharma.com/20191231/role/statement-note-2-summary-of-significant-accounting-policies 25 false false R26.htm 025 - Disclosure - Note 3 - Fair Value Measurements (Tables) Sheet http://www.novabaypharma.com/20191231/role/statement-note-3-fair-value-measurements-tables Note 3 - Fair Value Measurements (Tables) Tables http://www.novabaypharma.com/20191231/role/statement-note-3-fair-value-measurements 26 false false R27.htm 026 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets (Tables) Sheet http://www.novabaypharma.com/20191231/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables Note 4 - Prepaid Expenses and Other Current Assets (Tables) Tables http://www.novabaypharma.com/20191231/role/statement-note-4-prepaid-expenses-and-other-current-assets 27 false false R28.htm 027 - Disclosure - Note 5 - Inventory (Tables) Sheet http://www.novabaypharma.com/20191231/role/statement-note-5-inventory-tables Note 5 - Inventory (Tables) Tables http://www.novabaypharma.com/20191231/role/statement-note-5-inventory 28 false false R29.htm 028 - Disclosure - Note 6 - Property and Equipment (Tables) Sheet http://www.novabaypharma.com/20191231/role/statement-note-6-property-and-equipment-tables Note 6 - Property and Equipment (Tables) Tables http://www.novabaypharma.com/20191231/role/statement-note-6-property-and-equipment 29 false false R30.htm 029 - Disclosure - Note 7 - Accrued Liabilities (Tables) Sheet http://www.novabaypharma.com/20191231/role/statement-note-7-accrued-liabilities-tables Note 7 - Accrued Liabilities (Tables) Tables http://www.novabaypharma.com/20191231/role/statement-note-7-accrued-liabilities 30 false false R31.htm 030 - Disclosure - Note 8 - Commitments and Contingencies (Tables) Sheet http://www.novabaypharma.com/20191231/role/statement-note-8-commitments-and-contingencies-tables Note 8 - Commitments and Contingencies (Tables) Tables http://www.novabaypharma.com/20191231/role/statement-note-8-commitments-and-contingencies 31 false false R32.htm 031 - Disclosure - Note 9 - Related Party Notes Payable (Tables) Notes http://www.novabaypharma.com/20191231/role/statement-note-9-related-party-notes-payable-tables Note 9 - Related Party Notes Payable (Tables) Tables http://www.novabaypharma.com/20191231/role/statement-note-9-related-party-notes-payable- 32 false false R33.htm 032 - Disclosure - Note 10 - Convertible Note (Tables) Sheet http://www.novabaypharma.com/20191231/role/statement-note-10-convertible-note-tables Note 10 - Convertible Note (Tables) Tables http://www.novabaypharma.com/20191231/role/statement-note-10-convertible-note- 33 false false R34.htm 033 - Disclosure - Note 11 - Warrant Liability (Tables) Sheet http://www.novabaypharma.com/20191231/role/statement-note-11-warrant-liability-tables Note 11 - Warrant Liability (Tables) Tables http://www.novabaypharma.com/20191231/role/statement-note-11-warrant-liability 34 false false R35.htm 034 - Disclosure - Note 12 - Stockholders' Equity (Tables) Sheet http://www.novabaypharma.com/20191231/role/statement-note-12-stockholders-equity-tables Note 12 - Stockholders' Equity (Tables) Tables http://www.novabaypharma.com/20191231/role/statement-note-12-stockholders-equity 35 false false R36.htm 035 - Disclosure - Note 13 - Equity-based Compensation (Tables) Sheet http://www.novabaypharma.com/20191231/role/statement-note-13-equitybased-compensation-tables Note 13 - Equity-based Compensation (Tables) Tables http://www.novabaypharma.com/20191231/role/statement-note-13-equitybased-compensation 36 false false R37.htm 036 - Disclosure - Note 14 - License, Collaboration and Distribution Agreements (Tables) Sheet http://www.novabaypharma.com/20191231/role/statement-note-14-license-collaboration-and-distribution-agreements-tables Note 14 - License, Collaboration and Distribution Agreements (Tables) Tables http://www.novabaypharma.com/20191231/role/statement-note-14-license-collaboration-and-distribution-agreements- 37 false false R38.htm 037 - Disclosure - Note 16 - Income Taxes (Tables) Sheet http://www.novabaypharma.com/20191231/role/statement-note-16-income-taxes-tables Note 16 - Income Taxes (Tables) Tables http://www.novabaypharma.com/20191231/role/statement-note-16-income-taxes 38 false false R39.htm 038 - Disclosure - Note 1 - Organization (Details Textual) Sheet http://www.novabaypharma.com/20191231/role/statement-note-1-organization-details-textual Note 1 - Organization (Details Textual) Details http://www.novabaypharma.com/20191231/role/statement-note-1-organization 39 false false R40.htm 039 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.novabaypharma.com/20191231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual Note 2 - Summary of Significant Accounting Policies (Details Textual) Details http://www.novabaypharma.com/20191231/role/statement-note-2-summary-of-significant-accounting-policies-tables 40 false false R41.htm 040 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Components of Cash, Cash Equivalents, and Restricted Cash (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-2-summary-of-significant-accounting-policies-components-of-cash-cash-equivalents-and-restricted-cash-details Note 2 - Summary of Significant Accounting Policies - Components of Cash, Cash Equivalents, and Restricted Cash (Details) Details 41 false false R42.htm 041 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Revenues and Accounts Receivable From Major Distribution Partners and Customers (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-2-summary-of-significant-accounting-policies-revenues-and-accounts-receivable-from-major-distribution-partners-and-customers-details Note 2 - Summary of Significant Accounting Policies - Revenues and Accounts Receivable From Major Distribution Partners and Customers (Details) Details 42 false false R43.htm 042 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Calculation of Basic and Diluted EPS (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-2-summary-of-significant-accounting-policies-calculation-of-basic-and-diluted-eps-details Note 2 - Summary of Significant Accounting Policies - Calculation of Basic and Diluted EPS (Details) Details 43 false false R44.htm 043 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Outstanding Stock Options and Stock Warrants Excluded From the Diluted Net Loss Per Share Computation (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-2-summary-of-significant-accounting-policies-outstanding-stock-options-and-stock-warrants-excluded-from-the-diluted-net-loss-per-share-computation-details Note 2 - Summary of Significant Accounting Policies - Outstanding Stock Options and Stock Warrants Excluded From the Diluted Net Loss Per Share Computation (Details) Details 44 false false R45.htm 044 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Impact of New Standard on Consolidated Balance Sheet (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-2-summary-of-significant-accounting-policies-impact-of-new-standard-on-consolidated-balance-sheet-details Note 2 - Summary of Significant Accounting Policies - Impact of New Standard on Consolidated Balance Sheet (Details) Details 45 false false R46.htm 045 - Disclosure - Note 3 - Fair Value Measurements (Details Textual) Sheet http://www.novabaypharma.com/20191231/role/statement-note-3-fair-value-measurements-details-textual Note 3 - Fair Value Measurements (Details Textual) Details http://www.novabaypharma.com/20191231/role/statement-note-3-fair-value-measurements-tables 46 false false R47.htm 046 - Disclosure - Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Details 47 false false R48.htm 047 - Disclosure - Note 3 - Fair Value Measurements - Fair Value of Warrant Liability (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-3-fair-value-measurements-fair-value-of-warrant-liability-details Note 3 - Fair Value Measurements - Fair Value of Warrant Liability (Details) Details 48 false false R49.htm 048 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) Details 49 false false R50.htm 049 - Disclosure - Note 5 - Inventory - Summary of Inventory (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-5-inventory-summary-of-inventory-details Note 5 - Inventory - Summary of Inventory (Details) Details 50 false false R51.htm 050 - Disclosure - Note 6 - Property and Equipment (Details Textual) Sheet http://www.novabaypharma.com/20191231/role/statement-note-6-property-and-equipment-details-textual Note 6 - Property and Equipment (Details Textual) Details http://www.novabaypharma.com/20191231/role/statement-note-6-property-and-equipment-tables 51 false false R52.htm 051 - Disclosure - Note 6 - Property and Equipment - Summary of Property and Equipment (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-6-property-and-equipment-summary-of-property-and-equipment-details Note 6 - Property and Equipment - Summary of Property and Equipment (Details) Details 52 false false R53.htm 052 - Disclosure - Note 7 - Accrued Liabilities - Summary of Accrued Liabilities (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-7-accrued-liabilities-summary-of-accrued-liabilities-details Note 7 - Accrued Liabilities - Summary of Accrued Liabilities (Details) Details 53 false false R54.htm 053 - Disclosure - Note 8 - Commitments and Contingencies (Details Textual) Sheet http://www.novabaypharma.com/20191231/role/statement-note-8-commitments-and-contingencies-details-textual Note 8 - Commitments and Contingencies (Details Textual) Details http://www.novabaypharma.com/20191231/role/statement-note-8-commitments-and-contingencies-tables 54 false false R55.htm 054 - Disclosure - Note 8 - Commitments and Contingencies - Lease Expense (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-8-commitments-and-contingencies-lease-expense-details Note 8 - Commitments and Contingencies - Lease Expense (Details) Details 55 false false R56.htm 055 - Disclosure - Note 8 - Commitments and Contingencies - Schedule of Future Lease Payments (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-8-commitments-and-contingencies-schedule-of-future-lease-payments-details Note 8 - Commitments and Contingencies - Schedule of Future Lease Payments (Details) Details 56 false false R57.htm 056 - Disclosure - Note 8 - Commitments and Contingencies - Schedule of Future Lease Payments to Be Received (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-8-commitments-and-contingencies-schedule-of-future-lease-payments-to-be-received-details Note 8 - Commitments and Contingencies - Schedule of Future Lease Payments to Be Received (Details) Details 57 false false R58.htm 057 - Disclosure - Note 9 - Related Party Notes Payable (Details Textual) Notes http://www.novabaypharma.com/20191231/role/statement-note-9-related-party-notes-payable-details-textual Note 9 - Related Party Notes Payable (Details Textual) Details http://www.novabaypharma.com/20191231/role/statement-note-9-related-party-notes-payable-tables 58 false false R59.htm 058 - Disclosure - Note 9 - Related Party Notes Payable - Schedule of related Party Debt (Details) Notes http://www.novabaypharma.com/20191231/role/statement-note-9-related-party-notes-payable-schedule-of-related-party-debt-details Note 9 - Related Party Notes Payable - Schedule of related Party Debt (Details) Details 59 false false R60.htm 059 - Disclosure - Note 10 - Convertible Note (Details Textual) Sheet http://www.novabaypharma.com/20191231/role/statement-note-10-convertible-note-details-textual Note 10 - Convertible Note (Details Textual) Details http://www.novabaypharma.com/20191231/role/statement-note-10-convertible-note-tables 60 false false R61.htm 060 - Disclosure - Note 10 - Convertible Note - Key Assumptions Used to Value the Combined Embedded Derivative (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-10-convertible-note-key-assumptions-used-to-value-the-combined-embedded-derivative-details Note 10 - Convertible Note - Key Assumptions Used to Value the Combined Embedded Derivative (Details) Details 61 false false R62.htm 061 - Disclosure - Note 10 - Convertible Note - Schedule of Convertible Note (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-10-convertible-note-schedule-of-convertible-note-details Note 10 - Convertible Note - Schedule of Convertible Note (Details) Details 62 false false R63.htm 062 - Disclosure - Note 10 - Convertible Note - Schedule of Maturity of Convertible Note (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-10-convertible-note-schedule-of-maturity-of-convertible-note-details Note 10 - Convertible Note - Schedule of Maturity of Convertible Note (Details) Details 63 false false R64.htm 063 - Disclosure - Note 11 - Warrant Liability (Details Textual) Sheet http://www.novabaypharma.com/20191231/role/statement-note-11-warrant-liability-details-textual Note 11 - Warrant Liability (Details Textual) Details http://www.novabaypharma.com/20191231/role/statement-note-11-warrant-liability-tables 64 false false R65.htm 064 - Disclosure - Note 11 - Warrant Liability - The Key Assumptions Used to Value the Warrants (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-11-warrant-liability-the-key-assumptions-used-to-value-the-warrants-details Note 11 - Warrant Liability - The Key Assumptions Used to Value the Warrants (Details) Details 65 false false R66.htm 065 - Disclosure - Note 11 - Warrant Liability - Outstanding Warrant Liability (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-11-warrant-liability-outstanding-warrant-liability-details Note 11 - Warrant Liability - Outstanding Warrant Liability (Details) Details 66 false false R67.htm 066 - Disclosure - Note 12 - Stockholders' Equity (Details Textual) Sheet http://www.novabaypharma.com/20191231/role/statement-note-12-stockholders-equity-details-textual Note 12 - Stockholders' Equity (Details Textual) Details http://www.novabaypharma.com/20191231/role/statement-note-12-stockholders-equity-tables 67 false false R68.htm 067 - Disclosure - Note 12 - Stockholders' Equity - Outstanding Warrants (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-12-stockholders-equity-outstanding-warrants-details Note 12 - Stockholders' Equity - Outstanding Warrants (Details) Details 68 false false R69.htm 068 - Disclosure - Note 13 - Equity-based Compensation (Details Textual) Sheet http://www.novabaypharma.com/20191231/role/statement-note-13-equitybased-compensation-details-textual Note 13 - Equity-based Compensation (Details Textual) Details http://www.novabaypharma.com/20191231/role/statement-note-13-equitybased-compensation-tables 69 false false R70.htm 069 - Disclosure - Note 13 - Equity-based Compensation - Stock Options Outstanding (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-13-equitybased-compensation-stock-options-outstanding-details Note 13 - Equity-based Compensation - Stock Options Outstanding (Details) Details 70 false false R71.htm 070 - Disclosure - Note 13 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Employees and Directors (Details) Sheet http://www.novabaypharma.com/20191231/role/statement--note-13-equitybased-compensation-weightedaverage-assumptions-used-in-determining-the-value-of-options-granted-to-employees-and-directors-details Note 13 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Employees and Directors (Details) Details 71 false false R72.htm 071 - Disclosure - Note 13 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Non-employees (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-13-equitybased-compensation-weightedaverage-assumptions-used-in-determining-the-value-of-options-granted-to-nonemployees-details Note 13 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Non-employees (Details) Details 72 false false R73.htm 072 - Disclosure - Note 13 - Equity-based Compensation - Summary of Stock-based Compensation Expense Included in Results of Operations (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-13-equitybased-compensation-summary-of-stockbased-compensation-expense-included-in-results-of-operations-details Note 13 - Equity-based Compensation - Summary of Stock-based Compensation Expense Included in Results of Operations (Details) Details 73 false false R74.htm 073 - Disclosure - Note 14 - License, Collaboration and Distribution Agreements (Details Textual) Sheet http://www.novabaypharma.com/20191231/role/statement-note-14-license-collaboration-and-distribution-agreements-details-textual Note 14 - License, Collaboration and Distribution Agreements (Details Textual) Details http://www.novabaypharma.com/20191231/role/statement-note-14-license-collaboration-and-distribution-agreements-tables 74 false false R75.htm 074 - Disclosure - Note 14 - License, Collaboration and Distribution Agreements - Changes in Assets and Liabilities (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-14-license-collaboration-and-distribution-agreements-changes-in-assets-and-liabilities-details Note 14 - License, Collaboration and Distribution Agreements - Changes in Assets and Liabilities (Details) Details 75 false false R76.htm 075 - Disclosure - Note 14 - License, Collaboration and Distribution Agreements - Total Revenues (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-14-license-collaboration-and-distribution-agreements-total-revenues-details Note 14 - License, Collaboration and Distribution Agreements - Total Revenues (Details) Details 76 false false R77.htm 076 - Disclosure - Note 14 - License, Collaboration and Distribution Agreements - Revenue Recognized (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-14-license-collaboration-and-distribution-agreements-revenue-recognized-details Note 14 - License, Collaboration and Distribution Agreements - Revenue Recognized (Details) Details 77 false false R78.htm 077 - Disclosure - Note 15 - Employee Benefit Plan (Details Textual) Sheet http://www.novabaypharma.com/20191231/role/statement-note-15-employee-benefit-plan-details-textual Note 15 - Employee Benefit Plan (Details Textual) Details http://www.novabaypharma.com/20191231/role/statement-note-15-employee-benefit-plan 78 false false R79.htm 078 - Disclosure - Note 16 - Income Taxes (Details Textual) Sheet http://www.novabaypharma.com/20191231/role/statement-note-16-income-taxes-details-textual Note 16 - Income Taxes (Details Textual) Details http://www.novabaypharma.com/20191231/role/statement-note-16-income-taxes-tables 79 false false R80.htm 079 - Disclosure - Note 16 - Income Taxes - Loss Before Provision for Income Taxes (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-16-income-taxes-loss-before-provision-for-income-taxes-details Note 16 - Income Taxes - Loss Before Provision for Income Taxes (Details) Details 80 false false R81.htm 080 - Disclosure - Note 16 - Income Taxes - Federal and State Income Tax Provisions (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-16-income-taxes-federal-and-state-income-tax-provisions-details Note 16 - Income Taxes - Federal and State Income Tax Provisions (Details) Details 81 false false R82.htm 081 - Disclosure - Note 16 - Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-16-income-taxes-summary-of-deferred-tax-assets-and-liabilities-details Note 16 - Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details) Details 82 false false R83.htm 082 - Disclosure - Note 16 - Income Taxes - Summary of Net operating Loss and Tax Credit Carryforwards (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-16-income-taxes-summary-of-net-operating-loss-and-tax-credit-carryforwards-details Note 16 - Income Taxes - Summary of Net operating Loss and Tax Credit Carryforwards (Details) Details 83 false false R84.htm 083 - Disclosure - Note 16 - Income Taxes - Unrecognized Tax Benefit (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-16-income-taxes-unrecognized-tax-benefit-details Note 16 - Income Taxes - Unrecognized Tax Benefit (Details) Details 84 false false R85.htm 084 - Disclosure - Note 16 - Income Taxes - Effective Income Tax Rate Reconciliation (Details) Sheet http://www.novabaypharma.com/20191231/role/statement-note-16-income-taxes-effective-income-tax-rate-reconciliation-details Note 16 - Income Taxes - Effective Income Tax Rate Reconciliation (Details) Details 85 false false R86.htm 085 - Disclosure - Note 17 - Related Party Transactions (Details Textual) Sheet http://www.novabaypharma.com/20191231/role/statement-note-17-related-party-transactions-details-textual Note 17 - Related Party Transactions (Details Textual) Details http://www.novabaypharma.com/20191231/role/statement-note-17-related-party-transactions 86 false false All Reports Book All Reports nby-20191231.xml nby-20191231.xsd nby-20191231_cal.xml nby-20191231_def.xml nby-20191231_lab.xml nby-20191231_pre.xml http://fasb.org/us-gaap/2019-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true